Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) currently has a daily average trading volume of 1.45M but it saw 1667967 shares traded in last market. With a market cap of 1.12B USD, the company’s current market price of $8.27 came falling about -0.84 while comparing to the previous closing price of $8.34. In past 52 weeks, the stock remained buoying in the range of price level as high as $10.67 and as low as $5.11.
Oppenheimer issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $33 and $31.
Over the week, AUPH’s stock price is moving 1.47% up while it is 2.22% when we observe its performance for the past one month. Year-to-date it is -7.91% down and over the past year, the stock is showing an upside performance of 43.08%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of 0.14 while estimate for next year EPS is 0.59. In next quarter, company is expected to be making quarterly sales of $64.5M as analysts are expecting the sales for current fiscal year at $258.98M and seeing the company making $307.09M in sales next year. Moreover, analysts are in estimates of $64.27M for current-quarter revenue.
Currently, Aurinia Pharmaceuticals Inc’s total number of outstanding shares is 137.75M with 9.84% of that held by the insiders while 47.77% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 9.66% and return on equity (ROE) at 11.23%. It has a price to earnings ratio (P/E ratio) of 29.94 while having a 10.91 of forward P/E ratio. Stock’s beta reads 1.19. Stock has a price to book (P/B) ratio of 3.25 while price to sale or P/S ratio amounts to 4.52. Its return on asset (ROA) is 7.80% on average.
